Latest Zetia news
Stratification Tool IDs Who Will Benefit From Adding Ezetimibe
by modernClinician Editorial Team
For patients stabilized after acute coronary syndrome, a nine-point risk stratification tool can identify patients who will derive benefit from the addition of ezetimibe to statin therapy, according to a study published in the Feb. 28 issue of the Journal of the American College of Cardiology.
Ezetimibe Plus Rosuvastatin Bests Rosuvastatin Alone
by modernClinician Editorial Team
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone, according to a study published online Aug. 10 in Cardiovascular Therapeutics.
Nutraceuticals Alone or With Ezetimibe Aid in Dyslipidemia
by modernClinician Editorial Team
For statin-intolerant patients with dyslipidemia with ischemic heart disease treated with percutaneous coronary intervention, nutraceuticals alone or in combination with ezetimibe improve the lipid profile, according to a study published in the Dec. 15 issue of The American Journal of Cardiology.
Editor's Recommendations
High-Dose Omega-3 Linked to A-Fib Risk in Patients With High CVD Risk 
Machine Learning LDL-C Equation Comparable to Original Martin-Hopkins 
Docosahexaenoic Acid Supplement Does Not Improve Cognitive Performance 
Placebo-Controlled Trial Shows Reduced LDL Cholesterol Levels With Enlicitide Related Articles
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes 
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines Monthly Specialist Briefings
Stay Connected
